Chardan Capital Initiates Coverage On Clearside Biomedical with Buy Rating, Announces Price Target of $6
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital has initiated coverage on Clearside Biomedical with a Buy rating and set a price target of $6.
August 21, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital has initiated coverage on Clearside Biomedical with a Buy rating and a price target of $6, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $6 by Chardan Capital suggests a positive sentiment towards Clearside Biomedical. This is likely to influence investor perception and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100